# Hemoglobin Evolution In Hemodialysis Patients Longitudinal Data Analysis Project 1

Trang Tu - Luong Vuong - Neamin Berhe - Thanh Chuong Cao

# Study objectives

## To investigate:

- The evolution of hemoglobin (Hgb) over time in hemodialysis patients
- How this evolution is influenced by EPO dose, iron deficiency status, age, and sex



#### Dataset

- Longitudinal data of 3823 hemodialysis patients over six months:
  - Monthly Hgb concentrations
  - Monthly Erythropoietin (EPO): EPO for the next month was decided by the Hgb level of the current month
  - Iron deficiency status at each month
  - Background data: age and sex
- Unbalanced data: not all patients were follow the whole six months

## Exploratory Data Analyses

- Individual-specific profiles
- Graphical methods to explore mean structure, variance structure and correlation structure
- ullet Test linear and quadratic relationship of each patient' Hgb levels and time:  $R^2_{meta}$

## Summary statistics

- Analysis of each time point: comparison about hemoglobin levels between female and male group at each time point
- Analysis of increment: subject-specific changes of hemoglobin from baseline  $(y_{i1})$  to the last observation  $(y_{in_i})$ :  $y_{in_i} y_{i1}$
- Area under the curve:

$$AUC_i = (t_{i2} - t_{i1})X(y_{i1} + y_{i2})/2 + (t_{i3} - t_{i2})X(y_{i2} + y_{i3})/2 + \dots$$

#### Multivariate model

• Initial model, with unstructured covariance:

$$\begin{split} Y_{ij} &= \beta_0 + \beta_1 \operatorname{age}_i + \beta_2 \operatorname{sex}_i + \beta_3 \operatorname{iron}_{ij} + \beta_4 \operatorname{dose}_{ij} + \beta_5 \operatorname{month}_j + \beta_6 \operatorname{month}_j^2 \\ &+ \beta_7 (\operatorname{dose}_{ij} \times \operatorname{age}_i) + \beta_8 (\operatorname{dose}_{ij} \times \operatorname{sex}_i) + \beta_9 (\operatorname{dose}_{ij} \times \operatorname{iron}_{ij}) + \beta_{10} (\operatorname{dose}_{ij} \times \operatorname{month}_j \times \beta_{11} (\operatorname{month}_j \times \operatorname{age}_i) + \beta_{12} (\operatorname{month}_j \times \operatorname{sex}_i) + \beta_{13} (\operatorname{month}_j \times \operatorname{iron}_{ij}) + \epsilon_{ij} \end{split}$$

- Reduce mean structure: F-test
- Compare different covariance structures using LR test: unstructured type, simple type, compound symmetry type, banded type, first-order autoregressive type and Toeplitz type

Two-stage analysis model

Stage 1: Linear regression model for each subject separately

Linear effect of time Hgb levels:

$$Y_{ij} = \beta_{1i} + \beta_{2i}t_{ij} + \epsilon_{ij}, \quad j = 0, \dots, 5$$

Stage 2: Explain variability in the subject-specific regression coefficients using known covariates

$$\beta_{1i} = \beta_0^{(1)} + \beta_{\text{Age}}^{(1)} \cdot \text{Age}_i + b_{1i}$$

$$\beta_{2i} = \beta_0^{(2)} + \beta_{\text{Age}}^{(2)} \cdot \text{Age}_i + b_{2i}$$
(2)

•  $b_{1i}$ ,  $b_{2i}$  are independent and  $\sim N(0,D)$ 

#### Linear mixed model

Four-stage model building process:

Step 1: elaborated LMM

$$Y_{i}=\beta_{0}+\beta_{1}Age_{i}+\beta_{2}Sex_{i}+\beta_{3}Dose_{ij}+\beta_{4}Iron_{ij}+\beta_{5}t_{ij}+\\ (\beta_{6}Age_{i}+\beta_{7}Sex_{i}+\beta_{7}Dose_{ij}+\beta_{8}Iron_{ij})t_{ij}+(\beta_{9}Age_{i}+\beta_{10}Sex_{i}+\beta_{11}Iron_{ij})Dose_{ij}+\\ b_{1i}+b_{2j}t_{ij}+\epsilon_{ij}$$
 (3)

Step 2: Test serial correlation function in residual covariance structure using REML log-likelihood

Step 3: Reduce random effect structure using Likelihood ratio test


Step 4: Reduce mean structure using F-test

 Compare model from step 3 with models removing interaction effects one by one, using F-test

## Results

## Exploratory Data Analysis

Individual profiles
 There exists both within-subject
 and between-subject variability
 in Hgb levels over time




## Results


## **Exploratory Data Analysis**

#### Mean structure

#### Variance structure




#### Covariance structure



# Results

# Summary statistics

• Analysis of increments:



## Multivariate model

### Finding parsimonous mean structure

• Reduce each term and perform F-test against the full model:

| Reduction                        | DF | F-value | Pr > F  |
|----------------------------------|----|---------|---------|
| $month^2$                        | 1  | 1.14    | 0.28    |
| dose*sex, dose*age and dose*iron | 3  | 1.63    | 0.18    |
| month*age and month*sex          | 5  | 1.95    | 0.08    |
| month*iron                       | 6  | 2.71    | 0.01    |
| month*dose                       | 6  | 6.73    | < 0.001 |

## Multivariate model

# Finding appropriate covariance structure

| Covariance structure        | Prameters | -2 Log<br>Likelihood | $G^2$  | df | p-value |
|-----------------------------|-----------|----------------------|--------|----|---------|
| Unstructured                | 21        | 27693.1              |        |    |         |
| Simple                      | 1         | 32007.9              | 4314.8 | 20 | < 0.001 |
| Compound symmetry           | 2         | 28358.7              | 665.6  | 19 | < 0.001 |
| Banded                      | 21        | 28948.1              | 1255.0 | 0  | < 0.001 |
| First-order autoregres-sive | 2         | 27755.5              | 62.4   | 19 | <0.001  |
| Toeplitz                    | 6         | 27735.8              | 42.7   | 15 | 0.002   |

## Multivariate model

#### Final model: unstructured covariance structure

Effect estimates:

| Effect                | Estimate | Standard Error | p-value |
|-----------------------|----------|----------------|---------|
| Intercept             | 10.61    | 0.09           | < 0.001 |
| Age                   | 0.003    | 0.001          | 0.03    |
| Male                  | 0.10     | 0.04           | 0.008   |
| Iron deficiency       | 0.17     | 0.03           | < 0.001 |
| EPO dose              | 0.0005   | 0.001          | 0.006   |
| Month                 | -0.04    | 0.01           | 0.01    |
| Dose*month            | 0.0005   | 0.0001         | < 0.001 |
| Iron deficiency*month | -0.05    | 0.02           | 0.01    |

# Two-stage analysis

## Stage-1 analysis

• Subject-specific linear regression model for patients with at least 2 measurements

| Variable  | N    | Mean  | Std Dev | Minimum | Maximum |
|-----------|------|-------|---------|---------|---------|
| Intercept | 2933 | 10.92 | 1.36    | 4.45    | 18.77   |
| month     | 2933 | 0.03  | 0.69    | -5.00   | 7.10    |

# Two-stage analysis

## Stage-2 analysis

• Effect of age on the intercept:

| Variable  | Parameter<br>Estimate | Standard Error | T Value | P-value |
|-----------|-----------------------|----------------|---------|---------|
| Intercept | 10.61                 | 0.108          | 98.53   | <0.0001 |
| AGE       | 0.005                 | 0.002          | 2.97    | 0.003   |

# Two-stage analysis

## Stage-2 analysis

• Effect of age on the slope:

| Variable  | Parameter<br>Estimate | Standard Error | T Value | P-value |
|-----------|-----------------------|----------------|---------|---------|
| Intercept | 0.157                 | 0.0553         | 2.83    | 0.005   |
| AGE       | -0.002                | 0.0009         | -2.17   | 0.030   |

## Linear mixed model

#### Mean structure was identical to the multivariate model

|                | LMM Estimate    |          | Multivariate    |          |
|----------------|-----------------|----------|-----------------|----------|
| Effect         | (SE)            | P-value  | Estimate (SE)   | P-value  |
| Intercept      | 10.62 (0.1)     | < 0.0001 | 10.61 (0.1)     | < 0.0001 |
| EPO dose       | 0.0005 (0.0002) | 0.005    | 0.0005 (0.0002) | 0.006    |
| Age            | 0.0027 (0.001)  | 0.04     | 0.0028 (0.001)  | 0.03     |
| Male           | 0.10 (0.04)     | 0.01     | 0.10 (0.04)     | 0.008    |
| ron deficiency | 0.17 (0.03)     | < 0.0001 | 0.17 (0.03)     | < 0.0001 |
| /lonth         | -0.028 (0.02)   | 0.07     | -0.038 (0.02)   | 0.02     |
| PO dose *      | 0.0005 (0.0001) | < 0.0001 | 0.0006 (0.0001) | < 0.0001 |
| nonth          |                 |          |                 |          |
| ron deficiency | -0.043 (0.02)   | 0.02     | -0.047 (0.02)   | 0.01     |
| k month        | . ,             |          | ` ,             |          |


## Linear mixed model

## Variance components

| Effect                      | Parameter  | Estimate (SE) |
|-----------------------------|------------|---------------|
| Covariance of $b_i$         |            |               |
| $var(b_{1i})$               | $d_{11}$   | 0.69 (0.056)  |
| Measurement error variance  |            |               |
| $var(\epsilon_{(1)ij})$     | $\sigma^2$ | 0.29 (0.016)  |
| Gaussian serial correlation |            |               |
| $var(\epsilon_{(2)ij})$     | $	au^2$    | 1.9 (0.13)    |

# Linear mixed model vs two-stage model

• Random slope against random intercept:



## Conclusions

- The mean Hgb concentration decreases over time
- Higher EPO dose »> higher Hgb over time
- Iron-deficient patients »> higher baseline Hgb, Hgb decreases over time
- Higher EPO dose »> higher baseline Hgb
- Older patients and male patients »> higher baseline Hgb
- Linear mixed model vs multivariate model

Thank you for your attention!